Henry Schein 10-Q 2026-09-26
HSIC · CIK 1000228 · Form 10-Q · Period ended September 26, 2026 · Filed November 3, 2026
Revenue rose 4.0% to $3.47 billion. Operating margin was 5.6%, against 4.9% a year earlier. Net income was $119 million.
8 sections, 163K characters. Original on sec.gov · ·
| Measure | Quarter ended Sep 26, 2026 | Quarter ended Sep 27, 2025 | Change |
|---|---|---|---|
| Revenue | $3.47B | $3.34B | +4.0% |
| Operating income | $193M | $164M | +17.7% |
| Net income | $119M | $101M | +17.8% |
| Diluted EPS | $1.06 | $0.84 | +26.2% |
| Operating margin* | 5.6% | 4.9% | +0.6 pts |
From the XBRL facts tagged to this filing; both columns are as reported in this filing. * Computed by filings.tools: free cash flow is operating cash flow less capital spending; operating margin is operating income over revenue.
Cover and table of contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
10-Q
(Mark One)
☒
QUARTERLY
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT
OF 1934
For the
quarterly
period ended
September 26, 2026
or
☐
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT
OF 1934
For the transition period from ____________ to ____________
Commission File Number:
0-27078
HENRY SCHEIN, INC.
(Exact name of registrant as specified in its charter)
Delaware
11-3136595
(State or other jurisdiction of
(I.R.S. Employer Identification No.)
incorporation or organization)
135 Duryea Road
Melville
,
New York
(Address of principal executive offices)
11747
(Zip Code)
(
)
843-5500
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $.01 per share
HSIC
The
Nasdaq
Global Select Market
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities
Exchange Act of 1934 during the preceding 12 months (or for such
shorter period that the registrant was required to file such
reports), and (2) has been subject to such filing requirements for the
past 90 days.
Yes
☒
No
☐
Indicate by check mark whether the registrant has submitted electronically every
Interactive Data File required to be submitted
pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during
the preceding 12 months (or for such shorter period
that the registrant was required to submit such files).
Yes
☒
No
☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller
reporting company, or an emerging growth company.
See the definitions of “large accelerated filer,”
“accelerated filer,”
“smaller reporting company,”
and “emerging growth company”
in Rule 12b-2 of the Exchange Act.
Large accelerated filer
☒
Accelerated filer
☐
Non-accelerated filer
☐
Smaller reporting company
☐
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for
complying with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act.
☐
Indicate by check mark whether the registrant is a shell company (as defined
in Rule 12b-2 of the Exchange Act).
Yes
☐
No
☒
As of October 26, 2026,
there were
110,538,542
shares of the registrant’s common stock outstanding.
HENRY SCHEIN, INC.
INDEX
Page
Condensed Consolidated Financial Statements:
Condensed Consolidated Balance Sheets
as of September 26, 2026 and December 27, 2025
Condensed Consolidated Statements of Income
for the three and nine months ended
September 26, 2026 and September 27, 2025
Condensed Consolidated Statements of Comprehensive Income
three and nine months ended September 26, 2026 and September 27, 2025
Condensed Consolidated Statement of Changes in Stockholders' Equity
for the three months ended September 26, 2026 and September 27, 2025
Condensed Consolidated Statement of Changes in Stockholders' Equity
September 26, 2026 and September 27, 2025
Condensed Consolidated Statements of Cash Flows
September 26, 2026 and September 27, 2025
Notes to Condensed Consolidated Financial Statements
Note 1 – Basis of Presentation
Note 2 – Significant Accounting Policies, Accounting Pronouncements Recently Adopted
and Recently Issued Accounting Pronouncements
Note 3 – Net Sales from Contracts with Customers
Note 5 – Business Acquisitions
Note 6 – Fair Value Measurements
Note 9 – Plan of Restructuring and Related Costs
Note 11 – Stock-Based Compensation
Note 12 – Redeemable Noncontrolling Interests
Note 13 – Comprehensive Income
Note 15 – Supplemental Cash Flow Information
Note 16 – Related Party Transactions
Note 17 – KKR Investment and Accelerated Share Repurchase Program
Management's Discussion and Analysis of
Financial Condition and Results of Operations
Quantitative and Qualitative Disclosures About Market Risk
Unregistered Sales of Equity Securities and Use of Proceeds
See accompanying notes.
PART
I. FINANCIAL INFORMATION
Item 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
HENRY SCHEIN, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in millions, except share data)
September 26,
December 27,
2026
2025
(unaudited)
ASSETS
Current assets:
Cash and cash equivalents
$
$
Accounts receivable, net of allowance for credit losses of $
and $
(1)
1,875
1,651
Inventories, net
2,050
2,002
Prepaid expenses and other
Total current assets
4,776
4,464
Property and equipment, net
Operating lease right-of-use assets
Goodwill
4,270
4,213
Other intangibles, net
1,018
Investments and other
Total assets
$
11,510
$
11,215
LIABILITIES, REDEEMABLE NONCONTROLLING INTERESTS AND
STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable
$
1,203
$
1,154
Bank credit lines
1,000
Current maturities of long-term debt
Operating lease liabilities
Accrued expenses:
Payroll and related
Taxes
Other
Total current liabilities
3,598
3,228
Long-term debt (1)
2,382
2,310
Deferred income taxes
Operating lease liabilities
Other liabilities
Total liabilities
6,779
6,421
Redeemable noncontrolling interests
Commitments and contingencies
(nil)
(nil)
Stockholders' equity:
Preferred stock, $
0.01
par value,
1,000,000
shares authorized,
none
outstanding
-
-
Common stock, $
0.01
par value,
480,000,000
shares authorized,
110,538,632
issued and outstanding on September 26, 2026 and
115,771,149
issued and outstanding on December 27, 2025
Additional paid-in capital
Retained earnings
3,205
3,293
Accumulated other comprehensive loss
(187)
(226)
Total Henry Schein, Inc. stockholders' equity
3,159
3,245
Noncontrolling interests
Total stockholders' equity
3,817
3,899
Total liabilities, redeemable noncontrolling
interests and stockholders' equity
$
11,510
$
11,215
(1)
Amounts presented include balances held by our consolidated variable interest entity (“VIE”).
At September 26, 2026 and
December 27, 2025, amounts include trade accounts receivable of $
million and $
million, respectively, and long-term debt
of $
million and $
million, respectively.
See
Note 1 – Basis of Presentation
for further information.
See accompanying notes.
HENRY SCHEIN, INC.
CONDENSED CONSOLIDATED STATEMENTS
OF INCOME
(in millions,
except share and per share data)
(unaudited)
Three Months Ended
Nine Months Ended
September 26,
September 27,
September 26,
September 27,
2026
2025
2026
2025
Net sales
$
3,471
$
3,339
$
10,297
$
9,747
Cost of sales
2,366
2,313
7,021
6,705
Gross profit
1,105
1,026
3,276
3,042
Operating expenses:
Selling, general and administrative
2,459
2,276
Depreciation and amortization
Restructuring and related costs
Operating income
Other income (expense):
Interest income
Interest expense
(42)
(38)
(124)
(111)
Other, net
-
(1)
(3)
Income before taxes, equity in earnings of affiliates and
noncontrolling interests
Income taxes
(37)
(28)
(109)
(94)
Equity in earnings of affiliates, net of tax
Net income
Less: Net income attributable to noncontrolling interests
(7)
(8)
(20)
(19)
Net income attributable to Henry Schein, Inc.
$
$
$
$
Earnings per share attributable to Henry Schein, Inc.:
Basic
$
1.07
$
0.84
$
2.83
$
2.44
Diluted
$
1.06
$
0.84
$
2.80
$
2.42
Weighted-average common
shares outstanding:
Basic
111,272,868
120,199,552
113,220,442
121,965,991
Diluted
112,538,936
121,036,247
114,338,114
122,840,062
See accompanying notes.
HENRY SCHEIN, INC.
CONDENSED CONSOLIDATED STATEMENTS
OF COMPREHENSIVE INCOME
(in millions)
(unaudited)
Three Months Ended
Nine Months Ended
September 26,
September 27,
September 26,
September 27,
2026
2025
2026
2025
Net income
$
$
$
$
Other comprehensive income, net of tax:
Foreign currency translation gain (loss)
(3)
(1)
Unrealized gain (loss) from hedging activities
-
(22)
Other comprehensive income (loss), net of tax
(3)
Comprehensive income
Comprehensive income attributable to noncontrolling interests:
Net income
(7)
(8)
(20)
(19)
Foreign currency translation loss (gain)
-
(4)
(29)
Comprehensive income attributable to noncontrolling
interests
(7)
(6)
(24)
(48)
Comprehensive income attributable to Henry Schein, Inc.
$
$
$
$
See accompanying notes.
HENRY SCHEIN, INC.
CONDENSED CONSOLIDATED STATEMENTS
OF CHANGES IN
STOCKHOLDERS’ EQUITY
(in millions, except share data)
(unaudited)
Accumulated
Common Stock
Additional
Other
Total
$0.01 Par Value
Paid-in
Retained
Comprehensive
Noncontrolling
Stockholders’
Shares
Amount
Capital
Earnings
Income (Loss)
Interests
Equity
Balance, June 27, 2026
111,916,222
$
$
$
3,200
$
(184)
$
$
3,817
Net income (excluding loss of $
attributable to Redeemable
noncontrolling interests)
-
-
-
-
Foreign currency translation gain (excluding $
attributable to Redeemable noncontrolling interests)
-
-
-
-
(3)
-
(3)
Unrealized gain from hedging activities,
net of tax of $
-
-
-
-
-
-
-
Distributions from noncontrolling shareholders
-
-
-
-
-
(11)
(11)
Change in fair value of redeemable securities
-
-
(21)
-
-
-
(21)
Noncontrolling interests and adjustments related to
business acquisitions and contingent consideration
-
-
-
-
-
Repurchase and retirement of common stock
(1,442,218)
-
(12)
(114)
-
-
(126)
Stock issued upon exercise of stock options
28,682
-
-
-
-
Stock-based compensation expense
71,459
-
-
-
-
Shares withheld for payroll taxes
(35,597)
-
(2)
-
-
-
(2)
Settlement of stock-based compensation awards
-
-
-
-
-
-
Balance, September 26, 2026
110,538,632
$
$
$
3,205
$
(187)
$
$
3,817
Accumulated
Common Stock
Additional
Other
Total
$0.01 Par Value
Paid-in
Retained
Comprehensive
Noncontrolling
Stockholders’
Shares
Amount
Capital
Earnings
Income (Loss)
Interests
Equity
Balance, June 28, 2025
121,895,045
$
$
$
3,485
$
(227)
$
$
4,088
Net income (excluding loss of $
attributable to Redeemable
noncontrolling interests)
-
-
-
-
Foreign currency translation gain (loss) (excluding loss of $
attributable to Redeemable noncontrolling interests)
-
-
-
-
(1)
-
Unrealized gain from hedging activities,
net of tax of $
-
-
-
-
-
Contributions from noncontrolling shareholders
-
-
-
-
-
Change in fair value of redeemable securities
-
-
(12)
-
-
-
(12)
Noncontrolling interests and adjustments related to
business acquisitions and contingent consideration
-
-
-
-
-
Repurchase and retirement of common stock
(3,335,985)
-
(211)
-
-
(204)
Stock issued upon exercise of stock options
2,446
-
-
-
-
-
-
Stock-based compensation expense
9,789
-
-
-
Shares withheld for payroll taxes
(3,442)
-
-
-
-
-
-
Settlement of stock-based compensation awards
-
-
-
-
-
-
Balance, September 27, 2025
118,567,917
$
$
$
3,375
$
(222)
$
$
4,023
See accompanying notes.
HENRY SCHEIN, INC.
CONDENSED CONSOLIDATED STATEMENTS
OF CHANGES IN
STOCKHOLDERS' EQUITY
(in millions, except share data)
(unaudited)
Accumulated
Common Stock
Additional
Other
Total
$0.01 Par Value
Paid-in
Retained
Comprehensive
Noncontrolling
Stockholders’
Shares
Amount
Capital
Earnings
Income (Loss)
Interests
Equity
Balance, December 27, 2025
115,771,149
$
$
$
3,293
$
(226)
$
$
3,899
Net income (excluding loss of $
attributable to Redeemable
noncontrolling interests)
-
-
-
-
Foreign currency translation gain (excluding gain of $
attributable to Redeemable noncontrolling interests)
-
-
-
-
-
Unrealized gain from hedging activities,
-
-
-
-
-
-
-
net of tax of $
-
-
-
-
-
Net distributions to noncontrolling shareholders
-
-
-
-
-
(18)
(18)
Change in fair value of redeemable securities
-
-
(55)
-
-
Showing the first 8K of 87K characters. Open the full section
Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS
Cautionary Note Regarding Forward-Looking Statements
In accordance with the “Safe Harbor” provisions of the Private Securities
Litigation Reform Act of 1995, we
provide the following cautionary remarks regarding important factors
that, among others, could cause future results
to differ materially from the forward-looking statements, expectations and assumptions
expressed or implied herein.
All forward-looking statements made by us are subject to risks and uncertainties
and are not guarantees of future
performance.
These forward-looking statements involve known and unknown
risks, uncertainties and other factors
that may cause our actual results, performance and achievements
or industry results to be materially different from
any future results, performance or achievements expressed or implied
by such forward-looking statements.
These
statements are generally identified by the use of such terms as “may,” “could,” “expect,” “intend,” “believe,”
“plan,” “estimate,” “forecast,” “project,” “anticipate,” “to be,” “to
make” or other comparable terms.
Factors that
could cause or contribute to such differences include, but are not limited to,
those discussed in the documents we
file with the Securities and Exchange Commission (SEC), including our Annual
Report on Form 10-K, and will be
contained in subsequent periodic filings we make with the SEC.
These documents identify in detail important risk
factors that could cause our actual performance to differ materially from current
expectations.
Risk factors and uncertainties that could cause actual results to differ materially from
current and historical results
include, but are not limited to: our dependence on third parties for
the manufacture and supply of our products and
where we manufacture products, our dependence on third parties
for raw materials or purchased components; risks
relating to the achievement of our strategic growth objectives, including
anticipated results of restructuring and
value creation initiatives; risks related to the Strategic Partnership Agreement with
KKR Hawaii Aggregator L.P.
entered into in January 2025; transitions in senior company leadership
(including, without limitation, our Chief
Executive Officer, Chief Financial Officer, and other executive officers); our ability to develop or acquire and
maintain and protect new products (particularly technology and specialty
products) and services and utilize new
technologies that achieve market acceptance with acceptable margins; transitional
challenges associated with
acquisitions and joint ventures, including the failure to achieve anticipated
synergies/benefits, as well as significant
demands on our operations, information systems, legal, regulatory, compliance, financial and human resources
functions in connection with acquisitions, dispositions and joint ventures; certain
provisions in our governing
documents that may discourage third-party acquisitions of us; adverse changes
in supplier rebates or other
purchasing incentives; risks related to the sale of corporate brand products;
risks related to activist investors;
security risks associated with our information systems and technology
products and services, such as cyberattacks
or other privacy or data security breaches (including the October 2023 incident);
effects of a highly competitive
(including, without limitation, competition from third-party online commerce sites)
and consolidating market;
political, economic and regulatory influences on the health care
industry; risks from expansion of customer
purchasing power and multi-tiered costing structures; increases in shipping costs
for our products or other service
issues with our third-party shippers, and increases in fuel and energy costs; changes
in laws and policies governing
manufacturing, development and investment in territories and countries
where we do business; general global and
domestic macro-economic and political conditions, including inflation,
deflation, recession, unemployment (and
corresponding increase in under-insured populations), consumer confidence,
sovereign debt levels, fluctuations in
energy pricing and the value of the U.S. dollar as compared to foreign currencies
and changes to other economic
indicators; failure to comply with existing and future regulatory
requirements, including relating to health care;
risks associated with the EU Medical Device Regulation; failure to comply with
laws and regulations relating to
health care fraud or other laws and regulations; failure to comply with
laws and regulations relating to the
collection, storage and processing of sensitive personal information or standards
in electronic health records or
transmissions; changes in tax legislation, changes in tax rates and availability
of certain tax deductions; risks related
to product liability, intellectual property and other claims; risks associated with customs policies or legislative
import restrictions; risks associated with disease outbreaks, epidemics,
pandemics (such as the COVID-19
pandemic), or similar wide-spread public health concerns and other
natural or man-made disasters; risks associated
with our global operations; the threat or outbreak of war (including, without
limitation, geopolitical wars), terrorism
or public unrest (including, without limitation, the wars in Ukraine
and Iran, the Israel-Gaza conflict and other
unrest and threats in the Middle East and the possibility of a wider European
or global conflict); changes to laws
and policies governing foreign trade, tariffs and sanctions or greater restrictions on
imports and exports, including
changes to international trade agreements and the current imposition of
(and the potential for additional) tariffs by
the U.S. on numerous countries and retaliatory tariffs; supply chain disruption; litigation
risks; new or unanticipated
litigation developments and the status of litigation matters; our dependence
on our senior management, employee
hiring and retention, increases in labor costs or health care costs, and our
relationships with customers, suppliers
and manufacturers; and disruptions in financial markets.
The order in which these factors appear should not be
construed to indicate their relative importance or priority.
We caution that these factors may not be exhaustive and that many of these factors are beyond our ability to control
or predict.
Accordingly, any forward-looking statements contained herein should not be relied upon as a prediction
of actual results.
We undertake no duty and have no obligation to update forward-looking statements except as
required by law.
Where You
Can Find Important Information
We may disclose important information through one or more of the following channels: SEC filings, public
conference calls and webcasts, press releases, the investor relations
page of our website (www.henryschein.com)
and the social media channels identified on the About Media Center page
of our website.
Recent Developments
Chief Financial Officer
On October 8, 2026, we announced that, effective November 4, 2026, Ronald N.
South will transition from his
position as Senior Vice President and Chief Financial Officer to the role of Senior Advisor.
Emmanuel Caprais,
Senior Financial Advisor as of October 12, 2026, will succeed Mr. South as Chief Financial Officer effective
November 4, 2026.
Tariffs and Related Economic Conditions
The U.S. has adopted new and increased tariffs on imports from countries, and
the scope, applicability and legal
basis for these tariffs continue to evolve through legislative and executive
actions, exemptions and ongoing judicial
challenges.
Although the U.S. Supreme Court invalidated certain tariffs imposed
under the International
Emergency Economic Powers Act (IEEPA), the U.S. government has subsequently implemented additional tariff
measures under other statutory authorities, and further changes to U.S. trade policy
remain possible.
Some
countries have imposed, or may impose, retaliatory tariffs or other restrictions on imports
from the U.S.
These
developments, and anticipated future developments, have created a
volatile environment for global trade, and new
trade policies with individual countries.
It is unclear whether, or the extent to which, the current tariffs on trade
with numerous countries will remain in place, or change, the exceptions
that may apply, and their timing.
The tariffs did not have an adverse material impact on our results of operations during
fiscal year 2025 and the nine
months ended September 26,
2026, although sales of U.S. dental equipment were temporarily impacted
by market
uncertainty related to tariffs in the second half of the quarter ended June 28, 2025.
During the three and nine months ended September 26, 2026, we
recognized a net benefit of $28 million and $30
million, respectively, related to previously paid IEEPA tariffs.
We expect to recognize additional benefit from
tariff refunds during the fourth quarter of 2026.
Executive-Level Overview
Henry Schein, Inc. is a solutions company for health care professionals powered
by a network of people and
technology.
We
believe we are the world’s largest provider of health care products and services primarily to office-
based dental and medical practitioners, as well as alternate sites of care.
We
serve more than one million customers
worldwide including dental practitioners, laboratories, physician practices and
ambulatory surgery centers, as well
as government, institutional health care clinics, home health providers, and
other alternate care clinics.
We
believe
that we have a strong brand identity due to our more than 94 years of experience
distributing health care products.
We
are headquartered in Melville, New York, employ approximately 25,000 people (of which more than 13,000 are
based outside of the United States) and have operations or affiliates in 34 countries and
territories.
Our broad
global footprint has evolved over time through our organic growth as well as through
contribution from strategic
acquisitions.
We
have established strategically located distribution centers around
the world to enable us to better serve our
customers and increase our operating efficiency.
This infrastructure, together with broad product and service
offerings at competitive prices, and a strong commitment to customer service, enables
us to be a single source of
supply for our customers’ needs.
As a distributor, we market and sell branded products as well as our own corporate brand portfolio of
cost-effective,
high-quality consumable merchandise products.
We
also manufacture, source and sell a range of company-owned
manufactured products, primarily implants, biomaterial products, endodontics, handpiece
and small equipment,
hand instrument and repair, restoratives, orthodontics, wound care, orthopedics and dental lab products.
We
have
achieved scale in these global businesses primarily through acquisitions, as
manufacturers of these products
typically do not utilize a distribution channel to serve customers.
Our reportable segments consist of: (i) Global Distribution and Value-Added Services; (ii) Global Specialty
Products; and (iii) Global Technology.
Global Distribution and Value-Added Services includes distribution to the global dental and medical markets of
national brand and corporate brand merchandise, as well as equipment and related
technical services.
This segment
also includes value-added services such as financial services, continuing education
services, consulting and other
services.
This segment also markets and sells under our own corporate brand,
a portfolio of cost-effective, high-
quality consumable merchandise.
Global Specialty Products includes manufacturing, marketing
and sales of dental
implant and biomaterial products; and endodontic, orthodontic and orthopedic
products and other health care-
related products and services.
Global Technology includes development and distribution of practice management
software, e-services and other products, which are distributed to health
care providers.
A key element to grow closer to our customers is our One Schein initiative, which
is a unified go-to-market
approach that enables practitioners to work synergistically with our supply chain, equipment
sales and service and
other value-added services, allowing our customers to leverage the
combined value that we offer through a single
program.
Specifically, One Schein provides customers with streamlined access to our comprehensive offering of
national brand products, corporate brand products and proprietary specialty products
and solutions (including
implant, orthodontic and endodontic products).
In addition, customers have access to a wide range of services,
including software and other value-added services.
Industry Overview
In recent years, the health care industry has increasingly focused on cost containment.
This trend has benefited
distributors capable of providing a broad array of products and services at low
prices.
It also has accelerated the
growth of DSOs, GPOs, HMOs, group practices, other managed care
accounts and collective buying groups, which,
in addition to their emphasis on obtaining products at competitive prices,
tend to favor distributors capable of
providing specialized management information support.
We
believe that the trend towards cost containment has
the potential to favorably affect demand for technology solutions, including software and
Artificial Intelligence
solutions, which can enhance the efficiency and facilitation of practice management.
Our operating results in recent years have been significantly affected by strategies
and transactions that we
undertook to expand our business, domestically and internationally, in part to address significant changes in the
health care industry, including consolidation of health care distribution companies, health care reform, trends
toward managed care, cuts in Medicare and collective purchasing arrangements.
Industry Consolidation
The health care products distribution industry, as it relates to office-based health care practitioners, is fragmented
and diverse.
The industry ranges from sole practitioners working out of
relatively small offices to group practices
or service organizations ranging in size from a few practitioners to a large number of practitioners who have
combined or otherwise associated their practices.
Due in part to the inability of office-based health care practitioners to store and manage
large quantities of supplies
in their offices, the distribution of health care supplies and small equipment to office-based health
care practitioners
has been characterized by frequent, small quantity orders, and a need for rapid,
reliable and substantially complete
order fulfillment.
The purchasing decisions within an office-based health care practice are typically
made by the
practitioner or an administrative assistant.
Supplies and small equipment are generally purchased from more
than
one distributor, with one generally serving as the primary supplier.
The trend of consolidation extends to our customer base.
Health care practitioners are increasingly seeking to
partner, affiliate or combine with larger entities such as hospitals, health systems, group practices or physician
hospital organizations.
In many cases, purchasing decisions for consolidated groups are
made at a centralized or
professional staff level; however, orders are delivered to the practitioners’ offices.
Our approach to acquisitions and joint ventures has been to expand our role as
a provider of products and services
to the health care industry.
This trend has resulted in our expansion into service areas that complement
our existing
operations and provide opportunities for us to develop synergies with, and thus strengthen, the acquired
businesses.
As industry consolidation continues, we believe that we are positioned
to capitalize on this trend, as we believe we
have the ability to support increased sales through our existing infrastructure, although
there can be no assurances
that we will be able to successfully accomplish this.
We
are focused on building relationships with decision makers
who do not reside in the office-based practitioner setting.
As the health care industry continues to change, we intend to continue to
seek opportunities to expand our role as a
provider of products and services to the health care industry.
There can be no assurance that we will be able to
successfully pursue any such opportunity or consummate any such transaction,
if pursued.
Aging Population and Other Market Influences
The health care products distribution industry continues to experience growth
due to the aging population,
increased health care awareness, the proliferation of medical technology
and testing, new pharmacological
treatments, and expanded third-party insurance coverage, partially offset by the effects of unemployment
on
insurance coverage.
In addition, the physician market continues to benefit from the
shift of procedures and
diagnostic testing from acute care settings to alternate-care sites, particularly
physicians’ offices.
According to the U.S. Census Bureau’s International Database, between 2026 and 2036, the 45 and older
population is expected to grow by approximately 10%.
Between 2026 and 2046, this age group is expected to grow
by approximately 17%.
This compares with expected total U.S. population growth rates of
approximately 4%
between 2026 and 2036
and approximately 6% between 2026 and 2046.
According to the U.S. Census Bureau’s International Database, in 2026 there are over seven million Americans
aged 85 years or older, the segment of the population most in need of long-term care and elder-care services.
By
the year 2050, that number is projected to increase to over 17 million.
The population aged 65 to 84 years is
projected to increase by approximately 12% during the same period.
As a result of these market dynamics, annual expenditures for health care services
continue to increase in the
United States.
We
believe that demand for our products and services will grow while
continuing to be impacted by
current and future operating, economic and industry conditions.
The Centers for Medicare and Medicaid Services,
or CMS, published “National Health Expenditure Data” indicating that
total national health care spending reached
approximately $5.3 trillion in 2024, or 18.0% of the nation’s gross domestic product, the benchmark measure
for
annual production of goods and services in the United States.
Health care spending is projected to reach
approximately $9.0 trillion by 2034, or 20.6% of the nation’s projected gross domestic product.
We
believe similar demographic changes are also occurring in other
markets we serve outside the U.S.
Government
Certain of our businesses involve the distribution, manufacturing, importation,
exportation, marketing, sale and/or
promotion of pharmaceuticals, medical devices and/or in vitro diagnostics
and in this regard, we are subject to
extensive local, state, federal and foreign governmental laws and regulations,
including as applicable to our
wholesale distribution of pharmaceuticals, medical devices, and in vitro diagnostics;
manufacturing activities; and
as part of our specialty home medical supplies businesses that distribute and sell
medical equipment and supplies
directly to patients.
Federal, state and certain foreign governments have also increased
enforcement activity in the
health care sector, particularly in areas of fraud and abuse, anti-bribery and anti-corruption, controlled substances
handling, medical device regulations and data privacy and security standards.
Certain of our businesses involve pharmaceuticals and/or medical devices,
including orthopaedic, in vitro
diagnostic devices, software regulated as a medical device, and sales of
medical equipment and supplies directly to
patients, that are paid for by third parties and/or patients and must operate in
compliance with a variety of
burdensome and complex coding, billing and record-keeping requirements
in order to substantiate claims for
payment under federal, state and commercial/private health care reimbursement
programs.
Government and private insurance programs fund a large portion of the total cost of medical
care, and there have
been efforts to limit such private and government insurance programs, including efforts, thus far
unsuccessful, to
seek repeal of the entire United States Patient Protection and Affordable Care Act,
as amended by the Health Care
and Education Reconciliation Act, each enacted in March 2010.
Certain of our businesses are subject to various additional federal, state,
local and foreign laws and regulations,
including with respect to the sale, transportation, importation, storage, handling
and disposal of hazardous or
potentially hazardous substances; “forever chemicals” such as per-and
polyfluoroalkyl substances; warnings related
to potential cancer or reproductive harm linked to chemicals; amalgam bans; pricing disclosures;
supply chain
transparency around human trafficking and forced labor practices; and safe working
conditions.
In addition,
activities to control medical costs, including laws and regulations lowering
reimbursement rates for
pharmaceuticals, medical devices, medical supplies and/or medical
treatments or services, are ongoing.
Laws and
regulations are subject to change and their evolving implementation may impact
our operations and financial
performance.
Certain of our businesses also maintain contracts with governmental agencies
and are subject to certain regulatory
requirements specific to government contractors.
Our businesses are generally subject to numerous laws and regulations that could
impact our financial performance,
and failure to comply with such laws or regulations could have a material
adverse effect on our businesses.
A more detailed discussion of laws, regulations and governmental activity
is included in Management’s Discussion
and Analysis of Financial Condition and Results of Operations, contained
in our Annual Report on Form 10-K for
the fiscal year ended December 27, 2025, filed with the SEC on February
24, 2026.
Results of Operations
The following tables summarize the significant components of our operating
results for the three and nine months
ended September 26, 2026 and September 27, 2025 and cash flows for the nine
months ended September 26, 2026
and September 27, 2025 (in millions):
Three Months Ended
Nine Months Ended
September 26,
September 27,
September 26,
September 27,
2026
2025
2026
2025
Operating results:
Net sales
$
3,471
$
3,339
$
10,297
$
9,747
Cost of sales
2,366
2,313
7,021
6,705
Gross profit
1,105
1,026
3,276
3,042
Operating expenses:
Selling, general and administrative
2,459
2,276
Depreciation and amortization
Restructuring and related costs
Operating income
$
$
$
$
Other expense, net
$
(33)
$
(30)
$
(99)
$
(90)
Income taxes
(37)
(28)
(109)
(94)
Net income
Net income attributable to Henry Schein, Inc.
Nine Months Ended
September 26,
September 27,
2026
2025
Cash flows:
Net cash provided by operating activities
$
$
Net cash used in investing activities
(173)
(253)
Net cash provided by (used in) financing activities
(138)
Plan of Restructuring and Related Costs
On August 6, 2024, we committed to a restructuring plan (the “2024
Plan”) to integrate our acquisitions, right-size
operations and further increase efficiencies.
We currently expect this plan to be completed by the end of 2027.
During the three months ended September 26, 2026 and September 27, 2025,
we recorded restructuring and related
charges associated with the 2024 Plan of $22 million and $34 million, respectively.
During the nine months ended
September 26, 2026 and September 27, 2025, we recorded restructuring
charges associated with the 2024 Plan of
$63 million and $82 million, respectively.
The restructuring and related costs for these periods primarily related to
severance and employee-related costs, costs to exit facilities and other
exit costs.
We expect to record restructuring
and related charges associated with the 2024 Plan through the end of 2027; however,
an estimate of the amount of
these charges for 2026
through 2027 has not yet been determined.
During the nine months ended September 26, 2026,
in connection with the 2024 Plan, we recorded a loss of $2
million related to the disposal of businesses in the Global Specialty Products
segment.
This amount is included in
the $63 million of restructuring and related charges discussed above.
Three Months Ended September 26, 2026 Compared to Three Months Ended September 27, 2025
Note: Percentages for Net Sales; Gross Profit; Operating Expenses; Other
Expense, Net; and Income Taxes are
based on actual values and may not recalculate due to rounding.
Our reportable segments are determined based on how our Chief Executive
Officer manages the business, assesses
performance and allocates resources.
We have three reportable segments:
(i) Global Distribution and Value-Added
Services; (ii) Global Specialty Products; and (iii) Global Technology.
Net Sales
Net sales by reportable segment and by major product or service type were
as follows:
September 26,
% of
September 27,
% of
Increase/(Decrease)
2026
Total
2025
Total
$
%
Global Distribution and Value
-Added Services
Global Dental Merchandise
(1)
$
1,295
37.3
%
$
1,210
36.2
%
$
7.0
%
Global Dental Equipment
(2)
12.9
13.2
2.3
Global Value
-Added Services
(3)
1.8
1.9
(2)
(4.8)
Global Dental
1,806
52.0
1,714
51.3
5.4
Global Medical
(4)
1,138
32.8
1,126
33.8
1.1
Total Global Distribution and Value
-Added Services
2,944
84.8
2,840
85.1
3.7
Global Specialty Products
(5)
11.3
11.0
6.1
Global Technology
(6)
5.2
5.2
5.2
Eliminations
(45)
(1.3)
(43)
(1.3)
(2)
n/a
Total
$
3,471
100.0
%
$
3,339
100.0
%
$
4.0
(1)
Includes infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, gypsum,
acrylics, articulators, abrasives, PPE products and our own corporate brand of consumable merchandise.
(2)
Includes dental chairs, delivery units and lights, digital dental laboratories, X-ray supplies and equipment, equipment repair
services and high-tech and digital restoration equipment.
(3)
Consists of financial services on a non-recourse basis, continuing education services for practitioners, consulting and other services.
(4)
Includes branded and generic pharmaceuticals, home solutions products, vaccines, surgical products, diagnostic tests, infection-
control products, X-ray products, equipment, PPE products, and vitamins.
(5)
Includes manufacturing, marketing and sales of dental implant and biomaterial products; and endodontic, orthodontic and
orthopedic products and other health care-related products and services.
(6)
Consists of the development and distribution of practice management software, e-services and other technology-enabled products
for health care providers.
The components of our sales growth were as follows:
Constant Currency
Growth/(Decline)
Total Constant
Currency
Growth/(Decline)
Foreign
Exchange
Impact
Total Sales
Growth/
(Decline)
Local Internal
Growth/(Decline)
Acquisition/
(Disposition)
Growth
Global Distribution and Value
-Added Services
Global Dental Merchandise
5.1
%
1.3
%
6.4
%
0.6
%
7.0
%
Global Dental Equipment
2.4
-
2.4
(0.1)
2.3
Global Value
-Added Services
(4.8)
-
(4.8)
-
(4.8)
Global Dental
4.1
0.9
5.0
0.4
5.4
Global Medical
1.0
-
1.0
0.1
1.1
Total Global Distribution and Value
-Added Services
2.9
0.5
3.4
0.3
3.7
Global Specialty Products
3.4
2.6
6.0
0.1
6.1
Global Technology
6.5
(1.3)
5.2
-
5.2
Total
3.1
0.7
3.8
0.2
4.0
Global Sales
Global net sales for the three months ended September 26, 2026 increased 4.0%,
attributable to internal growth of
3.1%, acquisition growth of 0.7%, and an increase in foreign exchange
of 0.2%.
The components of our sales
increase are presented in the table above.
Global Distribution and Value-Added Services Sales
Global Distribution and Value-Added Services net sales for the three months ended September 26, 2026 increased
3.7%.
The components of our sales increase are presented in
the table above.
The 4.1% increase in internally generated local currency dental sales was
primarily due to merchandise and
traditional equipment sales growth in the U.S. and merchandise and equipment
sales growth in international
markets.
The 1.0% increase in internally generated local currency medical sales was
attributable to growth of our Home
Solutions businesses,
partially offset by lower sales of point of care diagnostic test products and vaccines
related to
respiratory illness.
Global Specialty Products Sales
Global Specialty Products net sales for the three months ended September
26, 2026 increased 6.1%.
The
components of our sales increase are presented in the table above.
The 3.4% increase in internally generated local currency sales was attributable
to growth in our value and premium
implant businesses.
Global Technology Sales
Global Technology net sales for the three months ended September 26, 2026 increased 5.2%.
The components of
sales growth are presented in the table above.
The internally generated local currency increase of 6.5% in Global Technology sales was primarily attributable to
the increased rate of customer adoption of our core practice management solutions,
particularly our cloud-based
platforms, and a growth in revenue cycle management solutions.
Gross Profit
Gross profit and gross margin percentages by segment and in total were as follows:
September 26,
Gross
September 27,
Gross
Increase/(Decrease)
2026
Margin %
2025
Margin %
$
%
Global Distribution and Value
-Added Services
$
25.8
%
$
24.7
%
$
8.0
%
Global Specialty Products
56.8
55.3
9.0
Global Technology
68.9
66.9
8.4
Corporate
-
n/a
n/a
(5)
n/a
Total
$
1,105
31.8
$
1,026
30.7
$
7.7
Gross margin may not be comparable to that of other distribution companies due to
differing industry practices in
the classification of distribution network costs.
Gross margin percentages also vary across our segments, reflecting
differences in business models.
The Global Specialty Products segment generates
higher gross margins, as it
primarily includes products we develop and manufacture, compared
to the Global Distribution and Value-Added
Services segment, which principally distributes third-party and corporate brand
products.
While the Global
Specialty Products segment has increasingly leveraged the Global
Distribution and Value-Added Services segment
as a sales channel, the impact on overall margins has not been material.
The Global Technology segment also
generates higher gross margins, reflecting our role as both developer and provider of
software products and
services.
Within our Global Distribution and Value
-Added Services segment, gross profit margins may fluctuate between the
periods as a result of the changes in product mix and customer mix.
With respect to customer mix, sales to our
large-group customers are typically completed at lower gross margins as a result of
higher sales volumes, while
sales to office-based practitioners generally carry higher gross margins due to lower volumes.
The increase in Global Distribution and Value-Added Services gross profit for the three months ended September
26, 2026 compared to the prior-year-period is due primarily to increased internally
generated sales volume as
described above.
During the three months ended September 26, 2026, in the Global
Distribution and Value-Added
Services segment, we recognized a net benefit of $20 million related to
refunds for certain IEEPA tariffs previously
paid in the United States.
In addition to the benefit of the tariff refunds, the increase in gross margin rates was
attributable primarily to favorable business mix and benefits from our value creation
initiatives.
The increase in Global Specialty Products gross profit primarily reflects
increased internally generated sales
volume and gross profit from acquisitions.
During the three months ended September 26, 2026, in the Global
Specialty Products segment, we recognized a net benefit of $8 million
related to refunds for certain IEEPA tariffs
previously paid in the United States.
In addition to the benefit of the tariff refunds, the increase in gross margin
rates was due to product mix.
The increase in Global Technology gross profit is the result primarily of higher internally generated sales.
The
increase in gross margin rates was due to product mix.
Operating Expenses
Operating expenses (consisting of selling, general and administrative
expenses; depreciation and amortization; and
restructuring and related costs) by segment were as follows:
% of
% of
September 26,
Respective
September 27,
Respective
Increase/(Decrease)
2026
Sales
2025
Sales
$
%
Global Distribution and Value
-Added Services
$
18.2
%
$
18.5
%
$
2.4
%
Global Specialty Products
42.5
36.0
25.4
Global Technology
39.7
40.3
3.7
Corporate
n/a
n/a
n/a
23.8
22.9
8.1
Adjustments
(1)
n/a
n/a
(12)
n/a
Total operating expenses
$
26.3
$
25.8
$
5.7
(1)
Adjustments represent items excluded from segment operating income to enable comparison of financial results between periods.
These
items may vary independently of business performance.
September 26,
September 27,
2026
2025
Adjustments:
Restructuring and related costs
$
$
Acquisition intangible amortization
Change in contingent consideration
Litigation settlements
Costs associated with shareholder advisory matters and select implementation related value
creation consulting costs
Total adjustments
$
$
The net increase in operating expenses was
attributable to the following:
Operating Costs
(excluding
acquisitions)
Acquisitions
Adjustments
Total
Global Distribution and Value
-Added Services
$
$
$
-
$
Global Specialty Products
-
Global Technology
-
-
Corporate
-
-
-
Adjustments
-
-
(12)
(12)
Total operating expenses
$
$
$
(12)
$
The components of the net increase in total operating expenses are presented
in the table above.
The increase in
operating costs (excluding acquisitions) during the three months ended
September 26, 2026 was primarily
attributable to costs associated with our sales growth.
During the three months ended September 27, 2025, our
operating costs were favorably impacted by a benefit of $28 million related
to the remeasurement to the fair value
of a previously held equity investment within our Global Specialty Products
segment.
Other Expense, Net
Other expense, net was as follows:
September 26,
September 27,
Variance
2026
2025
$
%
Interest income
$
$
$
-
(4.4)
%
Interest expense
(42)
(38)
(4)
(11.5)
Other, net
-
(1)
(86.5)
Other expense, net
$
(33)
$
(30)
$
(3)
(14.7)
Interest income during the three months ended September 26, 2026
included $2 million of a benefit related to
refunds of certain IEEPA tariffs previously paid in the United States.
Interest expense increased primarily due to
increased borrowings.
Income Taxes
Our effective tax rate was 23.1% for the three months ended September 26, 2026, compared
to 21.3% for the prior
year period.
The difference between our effective and federal statutory tax rates primarily relates to state and
foreign income taxes and interest expense.
For the three months ended September 27, 2025, the difference was
further impacted by the tax treatment associated with the acquisition of a controlling
interest of a previously held
non-controlling equity investment.
Nine Months Ended September 26, 2026 Compared to Nine Months Ended September
27, 2025
Note: Percentages for Net Sales; Gross Profit; Operating Expenses; Other
Expense, Net; and Income Taxes are
based on actual values and may not recalculate due to rounding.
Our reportable segments are determined based on how our Chief Executive
Officer manages the business, assesses
performance and allocates resources.
We have three reportable segments: (i) Global Distribution and Value
-Added
Services; (ii) Global Specialty Products; and (iii) Global Technology.
Net Sales
Net sales by reportable segment and by major product or service type were
as follows:
September 26,
% of
September 27,
% of
Increase/(Decrease)
2026
Total
2025
Total
$
%
Global Distribution and Value
-Added Services
Global Dental Merchandise
(1)
$
3,924
38.1
%
$
3,613
37.1
%
$
8.6
%
Global Dental Equipment
(2)
1,322
12.8
1,263
13.0
4.7
Global Value
-Added Services
(3)
1.8
1.8
3.1
Global Dental
5,426
52.7
5,050
51.9
7.4
Global Medical
(4)
3,268
31.7
3,197
32.8
2.2
Total Global Distribution and Value
-Added Services
8,694
84.4
8,247
84.7
5.4
Global Specialty Products
(5)
1,207
11.7
1,122
11.5
7.6
Global Technology
(6)
5.2
5.1
6.8
Eliminations
(139)
(1.3)
(124)
(1.3)
(15)
n/a
Total
$
10,297
100.0
%
$
9,747
100.0
%
$
5.6
(1)
Includes infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, gypsum,
acrylics, articulators, abrasives, PPE products and our own corporate brand of consumable merchandise.
(2)
Includes dental chairs, delivery units and lights, digital dental laboratories, X-ray supplies and equipment, equipment repair
services and high-tech and digital restoration equipment.
(3)
Consists of financial services on a non-recourse basis, continuing education services for practitioners, consulting and other services.
(4)
Includes branded and generic pharmaceuticals, home solutions products, vaccines, surgical products, diagnostic tests, infection-
control products, X-ray products, equipment, PPE products, and vitamins.
(5)
Includes manufacturing, marketing and sales of dental implant and biomaterial products; and endodontic, orthodontic and
orthopedic products and other health care-related products and services.
(6)
Consists of the development and distribution of practice management software, e-services and other technology-enabled products
for health care providers.
The components of our sales growth/(decline) were as follows:
Constant Currency
Growth/(Decline)
Total Constant
Currency Growth
Foreign
Exchange
Impact
Total Sales
Growth
Local Internal
Growth
Acquisition/
(Disposition)
Growth
Global Distribution and Value
-Added Services
Global Dental Merchandise
4.7
%
1.3
%
6.0
%
2.6
%
8.6
%
Global Dental Equipment
2.7
-
2.7
2.0
4.7
Global Value
-Added Services
1.8
0.6
2.4
0.7
3.1
Global Dental
4.1
0.9
5.0
2.4
7.4
Global Medical
2.0
0.1
2.1
0.1
2.2
Total Global Distribution and Value
-Added Services
3.3
0.6
3.9
1.5
5.4
Global Specialty Products
2.6
2.7
5.3
2.3
7.6
Global Technology
7.5
(1.3)
6.2
0.6
6.8
Total
3.4
0.7
4.1
1.5
5.6
Global Sales
Global net sales for the nine months ended September 26, 2026
increased 5.6%, attributable to internal growth of
3.4%, acquisition growth of 0.7%, and an increase in foreign exchange
of 1.5%.
The components of our sales
increase are presented in the table above.
Global Distribution and Value-Added Services Sales
Global Distribution and Value-Added Services net sales for the nine months ended September 26, 2026 increased
5.4%.
The components of our sales increase are presented in
the table above.
The 4.1% increase in internally generated local currency dental sales was
primarily due to merchandise sales
growth in U.S. and international markets, growth in traditional dental equipment
in the U.S. and international
markets, partially offset by decreased sales in value-added services attributable to lower
brokerage revenue.
The 2.0% increase in internally generated local currency medical sales was
attributable to growth of our Home
Solutions business and dialysis products, partially offset by lower sales of point of
care diagnostic test products and
vaccines related to respiratory illness.
Global Specialty Products Sales
Global Specialty Products net sales for the nine months ended September
26, 2026 increased 7.6%.
The
components of our sales increase are presented in the table above.
The 2.6% increase in internally generated local currency sales was attributable
to growth in our value implant,
premium implant and biomaterial businesses.
Global Technology Sales
Global Technology net sales for the nine months ended September 26, 2026 increased 6.8%.
The components of
sales growth are presented in the table above.
The internally generated local currency increase of 7.5% in Global Technology sales was primarily attributable to
the increased rate of customer adoption of our core practice management solutions,
particularly our cloud-based
platforms as well as an increase in revenue cycle management solutions.
Gross Profit
Gross profit and gross margin percentages by segment and in total were as follows:
September 26,
Gross
September 27,
Gross
Increase/(Decrease)
2026
Margin %
2025
Margin %
$
%
Global Distribution and Value
-Added Services
$
2,234
25.7
%
$
2,071
25.1
%
$
7.9
%
Global Specialty Products
55.9
55.4
8.7
Global Technology
69.1
67.5
9.2
Corporate
(3)
n/a
n/a
(14)
n/a
Total
$
3,276
31.8
$
3,042
31.2
$
7.7
Gross margin may not be comparable to that of other distribution companies due to
differing industry practices in
the classification of distribution network costs.
Gross margin percentages also vary across our segments, reflecting
differences in business models.
The Global Specialty Products segment generates
higher gross margins, as it
primarily includes products we develop and manufacture, compared
to the Global Distribution and Value-Added
Services segment, which principally distributes third-party and corporate brand
products.
While the Global
Specialty Products segment has increasingly leveraged the Global
Distribution and Value-Added Services segment
as a sales channel, the impact on overall margins has not been material.
The Global Technology segment also
generates higher gross margins, reflecting our role as both developer and provider of
software products and
services.
Within our Global Distribution and Value
-Added Services segment, gross profit margins may fluctuate between the
periods as a result of the changes in product mix and customer mix.
With respect to customer mix, sales to our
large-group customers are typically completed at lower gross margins as a result of
higher sales volumes, while
sales to office-based practitioners generally carry higher gross margins due to lower volumes.
The increase in Global Distribution and Value-Added Services gross profit for the nine months ended September
26, 2026 compared to the prior-year-period is due primarily to increased internally
generated sales volume as
described above.
During the nine months ended September 26, 2026, in the Global
Distribution and Value-Added
Services segment, we recognized a net benefit of $21
million related to refunds for certain IEEPA tariffs previously
paid in the United States.
In addition to the benefit of the tariff refunds, the increase in gross
margin rates was
attributable primarily to favorable business mix and benefits from our value
creation initiatives.
The increase in Global Specialty Products gross profit primarily reflects
increased internally generated sales
volume and gross profit from acquisitions.
During the nine months ended September 26, 2026, in
the Global
Specialty Products segment, we recognized a net benefit of $9 million related
to refunds for certain IEEPA tariffs
previously paid in the United States.
In addition to the benefit of the tariff refunds, the increase in gross margin
rates was due to product mix.
The increase in Global Technology gross profit is the result primarily of higher internally generated sales.
The
increase in gross margin rates was due to product mix.
Operating Expenses
Operating expenses (consisting of selling, general and administrative
expenses; depreciation and amortization; and
restructuring and related costs) by segment were as follows:
% of
% of
September 26,
Respective
September 27,
Respective
Increase
2026
Sales
2025
Sales
$
%
Global Distribution and Value
-Added Services
$
1,649
19.0
%
$
1,567
19.0
%
$
5.2
%
Global Specialty Products
41.3
39.4
13.0
Global Technology
41.4
41.1
7.6
Corporate
n/a
n/a
n/a
2,494
24.2
2,325
23.9
7.3
Adjustments
(1)
n/a
n/a
n/a
Total operating expenses
$
2,730
26.5
$
2,552
26.2
$
7.0
(1)
Adjustments represent items excluded from segment operating income to enable comparison of financial results between periods.
These
items may vary independently of business performance.
September 26,
September 27,
2026
2025
Adjustments:
Restructuring and related costs
$
$
Acquisition intangible amortization
Cyber incident-insurance proceeds, net of third-party advisory expenses
-
(20)
Change in contingent consideration
-
Litigation settlements
Impairment of intangible assets
-
Costs associated with shareholder advisory matters and select implementation related value
creation consulting costs
Total adjustments
$
$
The net increase in operating expenses was
attributable to the following:
Operating Costs
(excluding
acquisitions)
Acquisitions
Adjustments
Total
Global Distribution and Value
-Added Services
$
$
$
-
$
Global Specialty Products
-
Global Technology
-
-
Corporate
-
-
-
Adjustments
-
-
Total operating expenses
$
$
$
$
The components of the net increase in total operating expenses are presented
in the table above.
The increase in
operating costs (excluding acquisitions) during the nine months ended September
26, 2026 was primarily
attributable to costs associated with our sales growth and the unfavorable impact
of foreign exchange rates.
During
the nine months ended September 26, 2026, our operating costs were
impacted by a benefit of $11 million related to
remeasurement to the fair value of a previously held equity investment within our
Global Specialty Products
segment.
During the nine months ended September 27, 2025, our operating costs
were impacted by a benefit of
$28 million related to remeasurement to the fair value of a previously held
equity investment within our Global
Specialty Products segment and a $4 million benefit within our Global
Distribution and Value-Added Services
segment.
Other Expense, Net
Other expense, net was as follows:
September 26,
September 27,
Variance
2026
2025
$
%
Interest income
$
$
$
-
(1.5)
%
Interest expense
(124)
(111)
(13)
(11.5)
Other, net
(3)
(113.3)
Other expense, net
$
(99)
$
(90)
$
(9)
(10.5)
Interest income during the nine months ended September 26, 2026 included
$2 million of a benefit related to
refunds of certain IEEPA tariffs previously paid in the United States.
Interest expense increased primarily due to
increased borrowings.
Income Taxes
Our effective tax rate was 24.5% for the nine months ended September 26, 2026, compared
to 23.5% for the prior
year period.
The difference between our effective and federal statutory tax rates primarily relates to
state and
foreign income taxes and interest expense.
For the nine months ended September 27, 2025, the difference was
further impacted by the tax treatment associated with the acquisition
of a controlling interest of a previously held
non-controlling equity investment.
Liquidity and Capital Resources
Our principal capital requirements have included funding of acquisitions, purchases
of additional noncontrolling
interests, repayments of debt principal, the funding of working capital needs,
purchases of fixed assets and
repurchases of common stock.
Working capital requirements generally result from increased sales, special
inventory forward buy-in opportunities and payment terms for receivables
and payables.
Historically, sales have
tended to be stronger during the second half of the year and special inventory
forward buy-in opportunities have
been most prevalent just before the end of the year, and have caused our working capital requirements
to be higher
from the end of the third quarter to the end of the first quarter of
the following year.
We finance our business primarily through cash generated from our operations, revolving credit facilities and debt
placements.
Please see
for further information.
Our ability to generate sufficient cash flows from
operations is dependent on the continued demand of our customers
for our products and services, and access to
products and services from our suppliers.
Our business requires a substantial investment in working capital, which
is susceptible to fluctuations during the
year as a result of inventory purchase patterns and seasonal demands.
Inventory purchase activity is a function of
sales activity, special inventory forward buy-in opportunities and our desired level of inventory.
We finance our business to provide adequate funding for at least 12 months.
Funding requirements are based on
forecasted profitability and working capital needs, which, on occasion, may
change.
Consequently, we may change
our funding structure to reflect any new requirements.
Our acquisition strategy is focused on investments in companies,
including high growth high margin businesses
aligned with our BOLD+1 strategy, that add new customers and sales teams, increase our geographic footprint
(whether entering a new country, such as emerging markets, or building scale where we have already invested in
businesses), and finally, those that enable us to access new products and technologies.
We believe that our cash and cash equivalents, our ability to access private debt markets and public equity markets,
and our available funds under existing credit facilities provide us with
sufficient liquidity to meet our currently
foreseeable short-term and long-term capital needs.
Net cash provided by operating activities was $306 million for the
nine months ended September 26, 2026,
compared to net cash provided by operating activities of $331 million for
the prior year.
The net change of $25
million was primarily attributable to an increase in operating income, partially
offset by changes in working capital
accounts (primarily accounts receivable, inventory, and other current assets).
Net cash used in investing activities was $173 million for the nine months
ended September 26, 2026, compared to
net cash used in investing activities of $253 million for the prior year.
The net change of $80 million was primarily
attributable to lower acquisition activity.
Net cash used in financing activities was $138 million for the nine
months ended September 26, 2026, compared to
net cash provided by financing activities of $18 million for the
prior year period.
In May 2025, funds affiliated
with KKR invested $250 million in Henry Schein through the purchase
of 3,285,152 shares of common stock.
Shortly thereafter, we initiated a $250 million accelerated share repurchase program to offset the resulting dilution.
As a result, during the nine months ended September 26, 2026 we had lower
proceeds from the issuance of
common stock and lower share repurchases compared to the prior year period.
Other factors contributing to the net
change of $156 million in financing activities primarily include lower net borrowings
as well as lower payments for
acquisitions of noncontrolling interests and contingent consideration.
The following table summarizes selected measures of liquidity and capital
resources:
September 26,
December 27,
2026
2025
Cash and cash equivalents
$
$
Working
capital
(1)
1,178
1,236
Debt:
Bank credit lines
$
1,000
$
Current maturities of long-term debt
Long-term debt
2,382
2,310
Total debt
$
3,524
$
3,107
Leases:
Current operating lease liabilities
$
$
Non-current operating lease liabilities
(1)
Includes $606 million and $491 million of certain accounts receivable which serve as security for U.S. trade accounts receivable
securitization at September 26, 2026 and December 27, 2025, respectively.
Our cash and cash equivalents consist of bank balances and investments
in money market funds representing
overnight investments with a high degree of liquidity.
Accounts receivable days sales outstanding and inventory turns
Our accounts receivable days sales outstanding from operations
increased to 46.6 days as of September 26, 2026
from 45.3 days as of September 27, 2025.
During the nine months ended September 26, 2026, we
wrote off
approximately $9 million of fully reserved accounts receivable against our
trade receivable reserve.
Our inventory
turns from operations decreased to 4.6 as of September 26, 2026 from 4.8
as of September 27, 2025.
Our working
capital accounts may be impacted by current and future economic conditions.
Leases
We
have operating and finance leases for corporate offices, office space, distribution and other
facilities, vehicles
and certain equipment.
Our leases have remaining terms of less than one year to approximately
22 years, some of
which may include options to extend the leases for up to 10 years.
As of September 26, 2026, our right-of-use
assets related to operating leases were $336 million and our current and
non-current operating lease liabilities were
$79 million and $288 million, respectively.
Stock Repurchases
On January 27, 2025, our Board of Directors authorized the repurchase
of up to an additional $500 million in shares
of our common stock.
On May 19, 2025, we executed an accelerated share repurchase program
to repurchase a total of $250 million of
our outstanding common stock based on volume-weighted average
prices.
In May 2025, we received 3,122,832
shares at an estimated fair value of $224
million.
In July 2025, we received an additional 368,651 shares at an
estimated fair value of $26 million, representing the final amount of shares
to be received under this accelerated
share repurchase program.
On September 8, 2025, our Board of Directors authorized the repurchase of
up to an additional $750 million in
shares of our common stock.
From March 3, 2003 through September 26, 2026, we repurchased $6.4 billion,
or 113,537,092 shares,
under our
common stock repurchase programs, with $330 million available
as of September 26, 2026 for future share
repurchases.
Redeemable Noncontrolling Interests
Some minority stockholders in certain of our subsidiaries have the right,
at certain times, to require us to acquire
their ownership interest in those entities at fair value.
Accounting Standards Codification Topic 480-10 is
applicable for noncontrolling interests where we are or may be required
to purchase all or a portion of the
outstanding interest in a consolidated subsidiary from the noncontrolling
interest holder under the terms of a put
option contained in contractual agreements.
As of September 26, 2026 and December 27, 2025, our balance
for
redeemable noncontrolling interests was $914 million and $895 million,
respectively.
Please see
Redeemable Noncontrolling Interests
for further information.
Critical Accounting Estimates
There have been no material changes in our critical accounting estimates
from those disclosed in Item 7 of our
Annual Report on Form 10-K for the year ended December 27, 2025.
Accounting Standards Update
For a discussion of accounting standards updates that have been adopted
or will be adopted, see
Accounting Policies, Accounting Pronouncements Recently Adopted and Recently Issued Accounting
of the Notes to the Condensed Consolidated Financial Statements
included under Item 1.
Item 3. QUANTITATIVE
QUANTITATIVE
AND QUALITATIVE
DISCLOSURES ABOUT MARKET RISK
There have been no material changes in our exposure to market risk
from that disclosed in Item 7A of our Annual
Report on Form 10-K for the year ended December 27, 2025.
Item 4. CONTROLS AND PROCEDURES
CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
Under the supervision and with the participation of management, including
our principal executive officer and
principal financial officer, we evaluated the effectiveness of the design and operation of our disclosure controls and
procedures as of the end of the period covered by this quarterly report
as such term is defined in Rules 13a-15(e)
and 15d-15(e) promulgated under the Securities Exchange Act of 1934, as
amended (the “Exchange Act”).
Based
on this evaluation, our management, including our principal executive
officer and principal financial officer,
concluded that our disclosure controls and procedures were effective as of September 26,
2026, to ensure that all
material information required to be disclosed by us in reports that we file
or submit under the Exchange Act is
accumulated and communicated to them as appropriate to allow timely
decisions regarding required disclosure and
that all such information is recorded, processed, summarized and reported
within the time periods specified in the
SEC’s rules and forms, and the rules of the Nasdaq stock exchange.
Changes in Internal Control over Financial Reporting
The combination of continued systems implementations, acquisition
integrations and value creation initiative
activities undertaken during the quarter ended September 26, 2026, and
carried over from prior quarters, when
considered in the aggregate, represents a material change in our
internal control over financial reporting.
During the quarter ended September 26, 2026, we continued systems
implementation activities for the phased roll-
out of a new e-commerce system for our Global Distribution and Value-Added Services segment in the U.S. and
Europe.
Also, we concluded systems implementation activities for the
implementation of a new global
consolidation and financial reporting system as well as the implementation
of a new ERP system for our Global
Technology segment in the U.S.
Additionally, post-acquisition integration related activities continued for businesses acquired during prior years
within our Global Specialty Products segment.
These acquisitions, the majority of which utilize separate
information and financial accounting systems, have been included
in our condensed consolidated financial
statements since their respective dates of acquisition.
Finally, activities related to value creation initiatives and the transition to a global business services model were
initiated for certain businesses.
These activities included current process knowledge transfer from
the Company to
the global business services provider as well as process monitoring by
the Company as the global business services
provider assumed processing responsibilities.
All continued systems implementations, acquisition integrations and value
creation initiative activities involve
necessary and appropriate change-management controls that are considered
in our quarterly assessment of the
design and operating effectiveness of our internal control over financial reporting.
Limitations of the Effectiveness of Internal Control
A control system, no matter how well conceived and operated, can provide
only reasonable, not absolute, assurance
that the objectives of the internal control system are met.
Because of the inherent limitations of any internal control
system, no evaluation of controls can provide absolute assurance that
all control issues, if any, within a company
have been detected.
PART
II.
OTHER INFORMATION
ITEM 1.
LEGAL PROCEEDINGS
For a discussion of Legal Proceedings, see
of the Notes to the Condensed
Consolidated Financial Statements included under Item 1.
Item 1A. RISK FACTORS
There have been no material changes from the risk factors disclosed in
Part I, Item 1A, of our Annual Report on
Form 10-K for the year ended December 27, 2025.
ITEM 2.
UNREGISTERED SALES OF EQUITY SECURITIES
AND USE OF PROCEEDS
Purchases of Equity Securities by the Issuer
Our share repurchase program, announced on March 3, 2003, originally
allowed us to repurchase up to two million
shares pre-stock splits (eight million shares post-stock splits) of our common
stock, which represented
approximately 2.3% of the shares outstanding at the commencement
of the program.
Subsequent additional
increases since 2003 that have aggregated to an additional $6.7 billion,
authorized by our Board, to the repurchase
program provide for a total of $6.8 billion (including $500 million authorized on
January 27, 2025 and an
additional $750 million authorized on September 8, 2025) of shares of our common
stock to be repurchased under
this program.
On May 19, 2025, we executed an accelerated share repurchase program to
repurchase a total of $250 million of
our outstanding common stock based on volume-weighted average prices.
In May 2025 we received 3,122,832
shares at an estimated fair value of $224 million.
In July 2025, we received an additional 368,651 shares at an
estimated fair value of $26 million, representing the final amount of shares
to be received under this accelerated
share repurchase program.
As of September 26, 2026, we had repurchased approximately $6.4 billion
of common stock (113,537,092 shares)
under these initiatives,
with $330 million available for future share repurchases.
The following table summarizes repurchases of our common stock
under our stock repurchase program during the
fiscal quarter ended September 26, 2026:
Total Number
Maximum Number
Total
of Shares
of Shares
Number
Average
Purchased as Part
that May Yet
of Shares
Price Paid
of Our Publicly
Be Purchased Under
Fiscal Month
Purchased (1)
Per Share
Announced Program
Our Program (2)
6/28/2026 through 8/01/2026
591,832
$
85.37
591,832
4,715,750
8/2/2026 through 8/29/2026
275,620
88.81
275,620
4,243,735
8/30/2026 through 9/26/2026
574,766
86.99
574,766
3,819,604
1,442,218
1,442,218
(1)
All repurchases were executed in the open market under our existing publicly announced authorized program.
(2)
The maximum number of shares that may yet be purchased under this program is determined at the end of each month based on the
closing price of our common stock at that time.
This table excludes shares withheld from employees to satisfy minimum tax withholding
requirements for equity-based transactions.
Item 5. OTHER INFORMATION
OTHER INFORMATION
On July 30, 2026, we announced that, effective October 30, 2026, Mark E. Mlotek,
the Company’s Executive Vice
President and Chief Strategic Officer, would transition out of his current role into a senior advisory role.
The
effective date of Mr. Mlotek’s transition has been extended to December 26, 2026.
As previously announced, Mr.
Mlotek will thereafter continue in a senior advisory role.
Item 6. EXHIBITS
EXHIBITS
Amended and Restated Executive Severance Plan, effective as of September 28,
Amended and Restated Henry Schein, Inc. Executive Change in Control Plan,
effective as of September 28, 2026.**+
Amendment No. 13 dated as of September 24, 2026 to Receivables Purchase
Agreement, dated as of April 17, 2013, by and among us, as servicer, HSFR,
Inc., as seller, the agent, and the various purchaser groups and purchaser agents
from time to time party thereto.+
First Amendment dated as of September 21, 2026 to the Amended and Restated
Term Loan Credit Agreement, dated as of June 6, 2025, among us, the several
lenders parties thereto, JPMorgan Chase Bank, N.A., as administrative agent
and the other agents party thereto.+
Fourth Amended and Restated Revolving Credit Agreement, dated as of
September 21, 2026, among us, the several lenders parties thereto, and
JPMorgan Chase Bank, N.A., as administrative agent, U.S. Bank National
Association, as syndication agent, and The Toronto-Dominion Bank, New York
Branch, Bank of America, N.A., UniCredit Bank GMBH, New York Branch,
the Bank of New York Mellon, ING Bank, N.V., Dublin Branch, HSBC Bank
USA, N.A. and MUFG Bank, Ltd., as co-documentation agents. (Incorporated
by reference to Exhibit 10.1 to our Current Report on Form 8-K filed on
Offer Letter between us and Emmanuel Caprais. (Incorporated by reference to
Exhibit 10.1 to our Current Report on Form 8-K filed on October 8, 2026.)**
Restrictive Covenant Agreement between us and Emmanuel Caprais.
(Incorporated by reference to Exhibit 10.2 to our Current Report on Form 8-K
Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.+
Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.+
Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.+
101.INS
Inline XBRL Instance Document - the instance document does not appear
in the
Interactive Data File because its XBRL tags are embedded within the Inline
XBRL document+
101.SCH
Inline XBRL Taxonomy Extension Schema Document+
101.CAL
Inline XBRL Taxonomy Extension Calculation Linkbase Document+
101.DEF
Inline XBRL Taxonomy Extension Definition Linkbase Document+
101.LAB
Inline XBRL Taxonomy Extension Label Linkbase Document+
101.PRE
Inline XBRL Taxonomy Extension Presentation Linkbase Document+
The cover page of Henry Schein, Inc.’s Quarterly Report on Form 10-Q for the
quarter ended September 26, 2026, formatted in Inline XBRL (included
within
Exhibit 101 attachments).+
+ Filed or furnished herewith.
** Indicates management contract or compensatory plan or agreement.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to
be signed on its behalf by the undersigned, thereunto duly authorized.
Henry Schein, Inc.
(Registrant)
By: /s/ RONALD N. SOUTH
Ronald N. South
Senior Vice President and
Chief Financial Officer
(Authorized Signatory and Principal Financial
and Accounting Officer)
Dated: November 3, 2026